아시아 태평양 2차 고옥살산뇨증 약물 시장, 유형별(Reloxaliase, Thiazide 이뇨제 및 보충제), 약물 유형(처방 및 일반 의약품), 인구 유형(어린이 및 성인), 최종 사용자(병원, 전문 병원, 가정 의료 및 기타), 유통 채널(병원 약국, 소매 약국, 온라인 약국 및 기타), 국가별(일본, 중국, 호주, 인도, 한국, 싱가포르, 인도네시아, 태국, 말레이시아, 필리핀, 베트남 및 기타 아시아 태평양 지역) 산업 동향 및 2028년까지의 예측
시장 분석 및 통찰력: 아시아 태평양 2차 고옥살산뇨증 약물 시장
2차 고옥살산뇨증 약물 시장은 2021년에서 2028년까지의 예측 기간 동안 시장 성장을 이룰 것으로 예상됩니다. Data Bridge Market Research는 시장이 2021년에서 2028년까지의 예측 기간 동안 67.3%의 CAGR로 성장하고 있으며 2020년 2억 1,690만 달러에서 2028년까지 8,346.46만 달러에 도달할 것으로 예상된다고 분석했습니다. 2차 고옥살산뇨증에 대한 표적 치료에 대한 수요가 높고 약물 개발에 중점을 둔 회사의 R&D 투자가 글로벌 2차 고옥살산뇨증 약물 시장 시장의 주요 동인이 될 가능성이 높습니다.
장 문제로 인해 높은 옥살산 농도의 흡수로 인해 다양한 장기와 조직에 영향을 미치는 다인자성 질환을 이차성 고옥살산뇨증이라고 하며, 극단적인 단계에서는 장내 고옥살산뇨증이라고 합니다. 이 질환은 비타민 C 와 같은 옥살산 또는 옥살산 전구체의 섭취가 질병의 주요 원인 중 하나이기 때문에 일부 질병으로 인한 식단 및 흡수 장애와 밀접한 관련이 있습니다. 이차성 고옥살산뇨증의 중요한 요인으로 알려진 박테리아인 옥살로박터 포르미게네스는 기능적 요구 사항을 완료하기 위한 핵심 에너지 요소로 옥살산을 사용하여 질병 발생에 중요한 역할을 합니다. 이러한 현재의 글로벌 약물 시나리오에서 항생제는 가장 많이 처방되는 약물 중 하나입니다. 항생제를 사용하면 장내 미세 환경에 영향을 미쳐 장내 세균총을 방해하고 따라서 이 박테리아의 식민지화를 억제하여 흡수 장애 위험을 증가시켜 이차성 고옥살산뇨증으로 이어질 수 있습니다.
Vitamin B6, calcium, magnesium and citrate supplement along with probiotics are prescribed in secondary hyperoxaluria with preventive care and availability of low oxalate food available in the market. The targeted treatment for secondary hyperoxaluria is in high demand, R&D investment in companies focusing on drug development, low dietary awareness in society and loss of oxalobacter formigenes due to increased usage of antibiotics are expected to drive the secondary hyperoxaluria drug market growth. Moreover, difficulty for maintaining low oxalate food and increasing number of bariatric surgery in the bolsters the secondary hyperoxaluria drug market growth.
The secondary hyperoxaluria drug market report provides details of market share, new developments, and impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the market scenario contact us for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.
Global Secondary Hyperoxaluria Drug Market Scope and Market Size
The secondary hyperoxaluria drug market is categorized into five notable segments which are based on the type, drug type, population type, end user and distribution channel. The growth among segments helps you analyse niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
- On the basis of type, the secondary hyperoxaluria drug is segmented into reloxaliase, thiazide diuretics and supplements. In 2021, supplements segment is dominating the secondary hyperoxaluria drug market as there is no targeted therapy available. However, some products are in the clinical trials and are expected to come to interstate commerce in near future. So management of the disease is done through supplements and dietary restrictions. Calcium supplements, magnesium supplements and other supplements serve as primary line of treatment along with dietary restrictions, fluid intake and probiotics which are used to maintain the gut flora.
- On the basis of drug type, the secondary hyperoxaluria drug is segmented into prescription and over the counter. In 2021, over the counter segment is dominating in the global secondary hyperoxaluria drug market as among all the products available for the treatment are generally supplements. After the successful diagnosis of the disease, the treatments suggested by physicians are available over the counter and a prescription is not necessary for these supplements to be consumed with regular diet owing to the reason for over the counter to dominate in the secondary hyperoxaluria drug market.
- On the basis of population type, the secondary hyperoxaluria drug is segmented into children and adults. In 2021, adults segment is dominating in the global secondary hyperoxaluria drug market as the diagnosis for secondary hyperoxaluria adults is usually carried out for indications of kidney stone and high oxalate excretion in the urine along with UTI. The prevalence of kidney stones is uncommon in children and the number of cases for the disease is comparatively very low when compared with adults.
- On the basis of end user, the secondary hyperoxaluria drug is segmented into hospitals, specialty clinics, home healthcare and others. In 2021, home healthcare segment is dominating the global secondary hyperoxaluria drug market owing to the fact that the current treatment comprises of supplements and thiazide diuretics. These treatment products are taken by patients at home without the help of any medical professional and supervision hence dominating the segment of the secondary hyperoxaluria drug market.
- On the basis of distribution channel, the secondary hyperoxaluria drug is segmented into hospital pharmacies, retail pharmacies, online pharmacies and others. In 2021, retail pharmacies segment is dominating in the secondary hyperoxaluria drug market as the numbers of these pharmacies are very high and increasing with year passing. They cater to majority of patients for buying drugs in traditional consumer purchase style. Moreover, retail pharmacies are focusing on broadening their services for better customer service.
Secondary Hyperoxaluria Drug Market Country Level Analysis
The secondary hyperoxaluria drug market is analysed and market size information is provided by country, type, drug type, population type, end user and distribution channel.
The countries covered in the secondary hyperoxaluria drug market report are Japan, China, Australia, India, South Korea, Singapore, Indonesia, Thailand, Malaysia, Philippines, Vietnam and Rest of Asia-Pacific.
Asia-Pacific is expected to grow with the CAGR in the forecasted periods as in the Asia-Pacific’s countries demand for secondary hyperoxaluria drug product is increasing very rapidly with the urbanization and availability of products. Japan is expected to dominate in the market in the Asia-Pacific market. Japan is one of the leading countries to inculcate secondary hyperoxaluria drug market.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
Increasing Number of Bariatric Surgery and Rising Disposable Income are Creating New Opportunities for Players in the Secondary Hyperoxaluria Drug Market
Secondary hyperoxaluria drug market also provides you with detailed market analysis for every country growth in particular industry with secondary hyperoxaluria product sales, impact of advancement in the secondary hyperoxaluria drug and changes in regulatory scenarios with their support for the secondary hyperoxaluria drug market. The data is available for historic period 2011 to 2019.
Competitive Landscape and Secondary Hyperoxaluria Drug Market Share Analysis
Secondary hyperoxaluria drug market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width and breath, application dominance, technology lifeline curve. The above data points provided are only related to the company’s focus related to secondary hyperoxaluria drug market.
The major companies providing secondary hyperoxaluria drug market are Nestlé, GlaxoSmithKline plc, Bayer AG, Pharmavite, Solgar Inc., Mission Pharmacal Company, Oystershell, Allena Pharmaceuticals, Inc., Celebrate Vitamins, Entring, LLC, OxThera, Renew Life Formulas, Inc., Synlogic, TIENS, Amway Corp., Infinitus (China), Now Foods, Nature's Bounty, among others. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.
The strategic initiatives by market players with capital investment for secondary hyperoxaluria is bridging the gap between secondary hyperoxaluria and its drugs.
- In November 2020, Bayer AG announced to start a G4A Digital health partnership program with the four new start-ups with a focus on cardio metabolic and renal disease, oncology and women’s health. This partnership is to shape the future of healthcare and to support the start-ups and will increase the strategic business development for the company.
- 2020년 8월, Pharmavite의 브랜드인 Nurish by Naturemade는 Walgreens를 통해 개인화된 비타민과 보충제를 개발하기 위해 Walgreens와 최초로 협업을 발표했습니다. 이 개발은 회사가 개별 영양소 격차를 메우는 데 도움이 될 것이며 회사의 미래 성장을 촉진하는 데 도움이 될 것입니다.
시장 참여자의 협력, 합작투자 및 기타 전략은 2차 고옥살산증 약물에 대한 회사 시장을 확대하고 있으며, 이를 통해 조직이 2차 고옥살산증 약물 시장에 대한 제공을 개선하는 데에도 도움이 됩니다.
SKU-
세계 최초의 시장 정보 클라우드 보고서에 온라인으로 접속하세요
- 대화형 데이터 분석 대시보드
- 높은 성장 잠재력 기회를 위한 회사 분석 대시보드
- 사용자 정의 및 질의를 위한 리서치 분석가 액세스
- 대화형 대시보드를 통한 경쟁자 분석
- 최신 뉴스, 업데이트 및 추세 분석
- 포괄적인 경쟁자 추적을 위한 벤치마크 분석의 힘 활용
목차
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF ASIA-PACIFIC SECONDARY HYPEROXALURIA DRUG MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 TYPE LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 MARKET END USER COVERAGE GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PIPELINE ANALYSIS
5 REGULATORY SCENARIO OF ASIA-PACIFIC SECONDARY HYPEROXALURIA DRUG MARKET
5.1 REGULATORY FRAMEWORK FOR PROBIOTICS
5.2 REGULATORY FRAMEWORK FOR EUROPE
6 MARKET OVERVIEW
6.1 DRIVERS
6.1.1 TARGETED TREATMENT FOR SECONDARY HYPEROXALURIA IS IN HIGH DEMAND
6.1.2 R&D INVESTMENT IN COMPANIES FOCUSING ON DRUG DEVELOPEMENT
6.1.3 LOW DIETARY AWARENESS IN UPPER SOCIO-ECONOMIC SOCIETY
6.1.4 INCREASED NUMBER OF CASES FOR SECONDARY HYPEROXALURIA
6.1.5 LOSS OF OXALOBACTER FORMIGENES
6.2 RESTRAINTS
6.2.1 LIMITED OPERATING REVENUE
6.2.2 HIGH COST OF TREATING SECONDARY HYPEROXALURIA
6.2.3 LIMITED SECONDARY THERAPEUTICS OPTION FOR TREATMENT
6.3 OPPORTUNITIES
6.3.1 DIFFICULTY IN MAINTAINING LOW OXALATE DIET
6.3.2 INCREASING NUMBER OF BARIATRIC SURGERY
6.3.3 REGULATORY SUPPORT FOR APPROVAL
6.3.4 RISING DISPOSABLE INCOME
6.4 CHALLENGES
6.4.1 DELAY IN DIAGNOSIS OF DISEASE LEADING TO NEED FOR RENAL REPLACEMENT
6.4.2 INCREASE FITNESS AWARENESS AMONG PEOPLE
6.4.3 INCREASE FLUID INTAKE AS A PREVENTIVE MEASURES
7 COVID-19 IMPACT ON ASIA-PACIFIC SECONDARY HYPEROXALURIA DRUG MARKET
7.1 OVERVIEW
7.2 PRICE IMPACT
7.3 IMPACT ON DEMAND
7.4 IMPACT ON SUPPLY CHAIN
7.5 STRATEGIC DECISIONS FOR MANUFACTURERS
7.6 CONCLUSION
8 ASIA-PACIFIC SECONDARY HYPEROXALURIA DRUG MARKET, BY TYPE
8.1 OVERVIEW
8.2 SUPPLEMENTS
8.2.1 OXALATE BINDING AGENTS
8.2.1.1 CALCIUM SUPPLEMENTS
8.2.1.2 MAGNESIUM SUPPLEMENTS
8.2.1.3 OTHERS
8.2.2 CITRATE SUPPLEMENTS
8.2.3 PYRIDOXINE SUPPLEMENTS
8.2.4 PROBIOTICS
8.3 THIAZIDE DIURETICS
8.4 RELOXALIASE
9 ASIA-PACIFIC SECONDARY HYPEROXALURIA DRUG MARKET, BY DRUG TYPE
9.1 OVERVIEW
9.2 OVER THE COUNTER
9.3 PRESCRIPTION
10 ASIA-PACIFIC SECONDARY HYPEROXALURIA DRUG MARKET, BY POPULATION TYPE
10.1 OVERVIEW
10.2 ADULTS
10.3 CHILDREN
11 ASIA-PACIFIC SECONDARY HYPEROXALURIA DRUG MARKET, BY END USER
11.1 OVERVIEW
11.2 HOME HEALTHCARE
11.3 HOSPITALS
11.4 SPECIALTY CLINICS
11.5 OTHERS
12 ASIA-PACIFIC SECONDARY HYPEROXALURIA DRUG MARKET, BY DISTRIBUTION CHANNEL
12.1 OVERVIEW
12.2 RETAIL PHARMACIES
12.3 HOSPITAL PHARMACIES
12.4 ONLINE PHARMACIES
12.5 OTHERS
13 ASIA-PACIFIC SECONDARY HYPEROXLURIA DRUG MARKET, BY GEOGRAPHY
13.1 ASIA-PACIFIC
13.1.1 CHINA
13.1.2 JAPAN
13.1.3 INDIA
13.1.4 AUSTRALIA
13.1.5 SOUTH KOREA
13.1.6 SINGAPORE
13.1.7 THAILAND
13.1.8 MALAYSIA
13.1.9 INDONESIA
13.1.10 PHILIPPINES
13.1.11 VIETNAM
13.1.12 REST OF ASIA-PACIFIC
14 ASIA-PACIFIC SECONDARY HYPEROXALURIA DRUG MARKET: COMPANY LANDSCAPE
14.1 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
15 COMPANY PROFILE
15.1 NESTLE
15.1.1 COMPANY SNAPSHOT
15.1.2 REVENUE ANALYSIS
15.1.3 COMPANY SHARE ANALYSIS
15.1.4 PRODUCT PORTFOLIO
15.1.5 RECENT DEVELOPMENTS
15.2 GLAXOSMITHKLINE PLC
15.2.1 COMPANY SNAPSHOT
15.2.2 REVENUE ANALYSIS
15.2.3 COMPANY SHARE ANALYSIS
15.2.4 PRODUCT PORTFOLIO
15.2.5 RECENT DEVELOPMENT
15.3 BAYER AG
15.3.1 COMPANY SNAPSHOT
15.3.2 REVENUE ANALYSIS
15.3.3 COMPANY SHARE ANALYSIS
15.3.4 PRODUCT PORTFOLIO
15.3.5 RECENT DEVELOPMENTS
15.4 NOW FOODS
15.4.1 COMPANY SNAPSHOT
15.4.2 COMPANY SHARE ANALYSIS
15.4.3 PRODUCT PORTFOLIO
15.4.4 RECENT DEVELOPMENTS
15.5 SOLGAR INC.
15.5.1 COMPANY SNAPSHOT
15.5.2 COMPANY SHARE ANALYSIS
15.5.3 PRODUCT PORTFOLIO
15.5.4 RECENT DEVELOPMENT
15.6 PHARMAVITE
15.6.1 COMPANY SNAPSHOT
15.6.2 PRODUCT PORTFOLIO
15.6.3 RECENT DEVELOPMENTS
15.7 INFINITUS (CHINA)
15.7.1 COMPANY SNAPSHOT
15.7.2 PRODUCT PORTFOLIO
15.7.3 RECENT DEVELOPMENTS
15.8 MISSION PHARMACAL COMPANY
15.8.1 COMPANY SNAPSHOT
15.8.2 PRODUCT PORTFOLIO
15.8.3 .RECENT DEVELOPMENT
15.9 OYSTER SHELL
15.9.1 COMPANY SNAPSHOT
15.9.2 PRODUCT PORTFOLIO
15.9.3 RECENT DEVELOPMENT
15.1 ALLENA PHARMACEUTICALS, INC.
15.10.1 COMPANY SNAPSHOT
15.10.2 PRODUCT PORTFOLIO
15.10.3 RECENT DEVELOPMENTS
15.11 AMWAY CORP.
15.11.1 COMPANY SNAPSHOT
15.11.2 PRODUCT PORTFOLIO
15.11.3 RECENT DEVELOPMENTS
15.12 CELEBRATE VITAMINS
15.12.1 COMPANY SNAPSHOT
15.12.2 PRODUCT PORTFOLIO
15.12.3 RECENT DEVELOPMENTS
15.13 ENTRING, LLC
15.13.1 COMPANY SNAPSHOT
15.13.2 PRODUCT PORTFOLIO
15.13.3 RECENT DEVELOPMENTS
15.14 NATURE’S BOUNTY
15.14.1 COMPANY SNAPSHOT
15.14.2 PRODUCT PORTFOLIO
15.14.3 RECENT DEVELOPMENT
15.15 OXTHERA
15.15.1 COMPANY SNAPSHOT
15.15.2 PRODUCT PORTFOLIO
15.15.3 RECENT DEVELOPMENT
15.16 RENEW LIFE FORMULAS, INC.
15.16.1 COMPANY SNAPSHOT
15.16.2 PRODUCT PORTFOLIO
15.16.3 RECENT DEVELOPMENTS
15.17 SYNLOGIC
15.17.1 COMPANY SNAPSHOT
15.17.2 REVENUE ANALYSIS
15.17.3 PRODUCT PORTFOLIO
15.17.4 RECENT DEVELOPMENTS
15.18 TIENS
15.18.1 COMPANY SNAPSHOT
15.18.2 PRODUCT PORTFOLIO
15.18.3 RECENT DEVELOPMENTS
16 QUESTIONNAIRE
17 RELATED REPORTS
표 목록
LIST OF TABLES
TABLE 1 ASIA-PACIFIC SECONDARY HYPEROXALURIA DRUG MARKET, PIPELINE ANALYSIS
TABLE 2 ASIA-PACIFIC SECONDARY HYPEROXALURIA DRUG MARKET: BY TYPE, 2019-2028 (USD MILLION)
TABLE 3 ASIA-PACIFIC SUPPLEMENTS IN SECONDARY HYPEROXALURIA DRUG MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 4 ASIA-PACIFIC SUPPLEMENTS IN SECONDARY HYPEROXALURIA DRUG MARKET: BY TYPE, 2019-2028 (USD MILLION)
TABLE 5 ASIA-PACIFIC OXALATE BINDING AGENTS IN SECONDARY HYPEROXALURIA DRUG MARKET: BY TYPE, 2019-2028 (USD MILLION)
TABLE 6 ASIA-PACIFIC THIAZIDE DIURETICS IN SECONDARY HYPEROXALURIA DRUG MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 7 ASIA-PACIFIC RELOXALIASE IN SECONDARY HYPEROXALURIA DRUG MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 8 ASIA-PACIFIC SECONDARY HYPEROXALURIA DRUG MARKET: BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 9 ASIA-PACIFIC OVER THE COUNTER IN SECONDARY HYPEROXALURIA DRUG MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 10 ASIA-PACIFIC PRESCRIPTION IN SECONDARY HYPEROXALURIA DRUG MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 11 ASIA-PACIFIC SECONDARY HYPEROXALURIA DRUG MARKET, BY POPULATION TYPE, 2019-2028 (USD MILLION)
TABLE 12 ASIA-PACIFIC ADULTS IN SECONDARY HYPEROXALURIA DRUG MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 13 ASIA-PACIFIC CHILDREN IN SECONDARY HYPEROXALURIA DRUG MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 14 ASIA-PACIFIC SECONDARY HYPEROXALURIA DRUG MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 15 ASIA-PACIFIC HOME HEALTHCARE IN SECONDARY HYPEROXALURIA DRUG MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 16 ASIA-PACIFIC HOSPITALS IN SECONDARY HYPEROXALURIA DRUG MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 17 ASIA-PACIFIC SPECIALTY CLINICS IN SECONDARY HYPEROXALURIA DRUG MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 18 ASIA-PACIFIC OTHERS IN SECONDARY HYPEROXALURIA DRUG MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 19 ASIA-PACIFIC SECONDARY HYPEROXALURIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 20 ASIA-PACIFIC RETAIL PHARMACIES IN SECONDARY HYPEROXALURIA DRUG MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 21 ASIA-PACIFIC HOSPITAL PHARMACIES IN SECONDARY HYPEROXALURIA DRUG MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 22 ASIA-PACIFIC ONLINE PHARMACIES IN SECONDARY HYPEROXALURIA DRUG MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 23 ASIA-PACIFIC OTHERS PHARMACIES IN SECONDARY HYPEROXALURIA DRUG MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 24 ASIA-PACIFIC SECONDARY HYPEROXALURIA DRUG MARKET, BY COUNTRY, 2019-2028 (USD MILLION)
TABLE 25 ASIA-PACIFIC SECONDARY HYPEROXALURIA DRUG MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 26 ASIA-PACIFIC SUPPLEMENTS IN SECONDARY HYPEROXALURIA DRUG MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 27 ASIA-PACIFIC OXALATE-BINDING AGENTS IN SECONDARY HYPEROXALURIA DRUG MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 28 ASIA-PACIFIC SECONDARY HYPEROXALURIA DRUG MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 29 ASIA-PACIFIC SECONDARY HYPEROXALURIA DRUG MARKET, BY POPULATION TYPE, 2019-2028 (USD MILLION)
TABLE 30 ASIA-PACIFIC SECONDARY HYPEROXALURIA DRUG MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 31 ASIA-PACIFIC SECONDARY HYPEROXALURIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 32 CHINA SECONDARY HYPEROXALURIA DRUG MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 33 CHINA SUPPLEMENTS IN SECONDARY HYPEROXALURIA DRUG MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 34 CHINA OXALATE-BINDING AGENTS IN SECONDARY HYPEROXALURIA DRUG MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 35 CHINA SECONDARY HYPEROXALURIA DRUG MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 36 CHINA SECONDARY HYPEROXALURIA DRUG MARKET, BY POPULATION TYPE, 2019-2028 (USD MILLION)
TABLE 37 CHINA SECONDARY HYPEROXALURIA DRUG MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 38 CHINA SECONDARY HYPEROXALURIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 39 JAPAN SECONDARY HYPEROXALURIA DRUG MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 40 JAPAN SUPPLEMENTS IN SECONDARY HYPEROXALURIA DRUG MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 41 JAPAN OXALATE-BINDING AGENTS IN SECONDARY HYPEROXALURIA DRUG MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 42 JAPAN SECONDARY HYPEROXALURIA DRUG MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 43 JAPAN SECONDARY HYPEROXALURIA DRUG MARKET, BY POPULATION TYPE, 2019-2028 (USD MILLION)
TABLE 44 JAPAN SECONDARY HYPEROXALURIA DRUG MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 45 JAPAN SECONDARY HYPEROXALURIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 46 INDIA SECONDARY HYPEROXALURIA DRUG MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 47 INDIA SUPPLEMENTS IN SECONDARY HYPEROXALURIA DRUG MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 48 INDIA OXALATE-BINDING AGENTS IN SECONDARY HYPEROXALURIA DRUG MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 49 INDIA SECONDARY HYPEROXALURIA DRUG MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 50 INDIA SECONDARY HYPEROXALURIA DRUG MARKET, BY POPULATION TYPE, 2019-2028 (USD MILLION)
TABLE 51 INDIA SECONDARY HYPEROXALURIA DRUG MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 52 INDIA SECONDARY HYPEROXALURIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 53 AUSTRALIA SECONDARY HYPEROXALURIA DRUG MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 54 AUSTRALIA SUPPLEMENTS IN SECONDARY HYPEROXALURIA DRUG MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 55 AUSTRALIA OXALATE-BINDING AGENTS IN SECONDARY HYPEROXALURIA DRUG MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 56 AUSTRALIA SECONDARY HYPEROXALURIA DRUG MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 57 AUSTRALIA SECONDARY HYPEROXALURIA DRUG MARKET, BY POPULATION TYPE, 2019-2028 (USD MILLION)
TABLE 58 AUSTRALIA SECONDARY HYPEROXALURIA DRUG MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 59 AUSTRALIA SECONDARY HYPEROXALURIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 60 SOUTH KOREA SECONDARY HYPEROXALURIA DRUG MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 61 SOUTH KOREA SUPPLEMENTS IN SECONDARY HYPEROXALURIA DRUG MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 62 SOUTH KOREA OXALATE-BINDING AGENTS IN SECONDARY HYPEROXALURIA DRUG MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 63 SOUTH KOREA SECONDARY HYPEROXALURIA DRUG MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 64 SOUTH KOREA SECONDARY HYPEROXALURIA DRUG MARKET, BY POPULATION TYPE, 2019-2028 (USD MILLION)
TABLE 65 SOUTH KOREA SECONDARY HYPEROXALURIA DRUG MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 66 SOUTH KOREA SECONDARY HYPEROXALURIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 67 SINGAPORE SECONDARY HYPEROXALURIA DRUG MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 68 SINGAPORE SUPPLEMENTS IN SECONDARY HYPEROXALURIA DRUG MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 69 SINGAPORE OXALATE-BINDING AGENTS IN SECONDARY HYPEROXALURIA DRUG MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 70 SINGAPORE SECONDARY HYPEROXALURIA DRUG MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 71 SINGAPORE SECONDARY HYPEROXALURIA DRUG MARKET, BY POPULATION TYPE, 2019-2028 (USD MILLION)
TABLE 72 SINGAPORE SECONDARY HYPEROXALURIA DRUG MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 73 SINGAPORE SECONDARY HYPEROXALURIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 74 THAILAND SECONDARY HYPEROXALURIA DRUG MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 75 THAILAND SUPPLEMENTS IN SECONDARY HYPEROXALURIA DRUG MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 76 THAILAND OXALATE-BINDING AGENTS IN SECONDARY HYPEROXALURIA DRUG MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 77 THAILAND SECONDARY HYPEROXALURIA DRUG MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 78 THAILAND SECONDARY HYPEROXALURIA DRUG MARKET, BY POPULATION TYPE, 2019-2028 (USD MILLION)
TABLE 79 THAILAND SECONDARY HYPEROXALURIA DRUG MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 80 THAILAND SECONDARY HYPEROXALURIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 81 MALAYSIA SECONDARY HYPEROXALURIA DRUG MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 82 MALAYSIA SUPPLEMENTS IN SECONDARY HYPEROXALURIA DRUG MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 83 MALAYSIA OXALATE-BINDING AGENTS IN SECONDARY HYPEROXALURIA DRUG MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 84 MALAYSIA SECONDARY HYPEROXALURIA DRUG MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 85 MALAYSIA SECONDARY HYPEROXALURIA DRUG MARKET, BY POPULATION TYPE, 2019-2028 (USD MILLION)
TABLE 86 MALAYSIA SECONDARY HYPEROXALURIA DRUG MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 87 MALAYSIA SECONDARY HYPEROXALURIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 88 INDONESIA SECONDARY HYPEROXALURIA DRUG MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 89 INDONESIA SUPPLEMENTS IN SECONDARY HYPEROXALURIA DRUG MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 90 SWITZRLAND OXALATE-BINDING AGENTS IN SECONDARY HYPEROXALURIA DRUG MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 91 INDONESIA SECONDARY HYPEROXALURIA DRUG MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 92 INDONESIA SECONDARY HYPEROXALURIA DRUG MARKET, BY POPULATION TYPE, 2019-2028 (USD MILLION)
TABLE 93 INDONESIA SECONDARY HYPEROXALURIA DRUG MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 94 INDONESIA SECONDARY HYPEROXALURIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 95 PHILIPPINES SECONDARY HYPEROXALURIA DRUG MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 96 PHILIPPINES SUPPLEMENTS IN SECONDARY HYPEROXALURIA DRUG MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 97 PHILIPPINES OXALATE-BINDING AGENTS IN SECONDARY HYPEROXALURIA DRUG MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 98 PHILIPPINES SECONDARY HYPEROXALURIA DRUG MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 99 PHILIPPINES SECONDARY HYPEROXALURIA DRUG MARKET, BY POPULATION TYPE, 2019-2028 (USD MILLION)
TABLE 100 PHILIPPINES SECONDARY HYPEROXALURIA DRUG MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 101 PHILIPPINES SECONDARY HYPEROXALURIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 102 VIETNAM SECONDARY HYPEROXALURIA DRUG MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 103 VIETNAM SUPPLEMENTS IN SECONDARY HYPEROXALURIA DRUG MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 104 VIETNAM OXALATE-BINDING AGENTS IN SECONDARY HYPEROXALURIA DRUG MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 105 VIETNAM SECONDARY HYPEROXALURIA DRUG MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 106 VIETNAM SECONDARY HYPEROXALURIA DRUG MARKET, BY POPULATION TYPE, 2019-2028 (USD MILLION)
TABLE 107 VIETNAM SECONDARY HYPEROXALURIA DRUG MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 108 VIETNAM SECONDARY HYPEROXALURIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 109 REST OF ASIA-PACIFIC SECONDARY HYPEROXALURIA DRUG MARKET, BY TYPE, 2019-2028 (USD MILLION)
그림 목록
LIST OF FIGURES
FIGURE 1 ASIA-PACIFIC SECONDARY HYPEROXALURIA DRUG MARKET: SEGMENTATION
FIGURE 2 ASIA-PACIFIC SECONDARY HYPEROXALURIA DRUG MARKET: DATA TRIANGULATION
FIGURE 3 ASIA-PACIFIC SECONDARY HYPEROXALURIA DRUG MARKET: DROC ANALYSIS
FIGURE 4 ASIA-PACIFIC SECONDARY HYPEROXALURIA DRUG MARKET: ASIA-PACIFIC VS REGIONAL MARKET ANALYSIS
FIGURE 5 ASIA-PACIFIC SECONDARY HYPEROXALURIA DRUG MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 ASIA-PACIFIC SECONDARY HYPEROXALURIA DRUG MARKET: MULTIVARIATE MODELLING
FIGURE 7 ASIA-PACIFIC SECONDARY HYPEROXALURIA DRUG MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 8 ASIA-PACIFIC SECONDARY HYPEROXALURIA DRUG MARKET: DBMR MARKET POSITION GRID
FIGURE 9 ASIA-PACIFIC SECONDARY HYPEROXALURIA DRUG MARKET: MARKET END USER COVERAGE GRID
FIGURE 10 ASIA-PACIFIC SECONDARY HYPEROXALURIA DRUG MARKET: VENDOR SHARE ANALYSIS
FIGURE 11 ASIA-PACIFIC SECONDARY HYPEROXALURIA DRUG MARKET: SEGMENTATION
FIGURE 12 LOW DIETARY AWARENESS IN UPPER SOCIO-ECONOMIC SOCIETY IS EXPECTED TO DRIVE THE ASIA-PACIFIC SECONDARY HYPEROXALURIA DRUG MARKET IN THE FORECAST PERIOD OF 2021 TO 2028
FIGURE 13 SUPPLEMENTS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE ASIA-PACIFIC SECONDARY HYPEROXALURIA DRUG MARKET IN 2021 & 2028
FIGURE 14 REGULATORY FRAMEWORK FOR PROBIOTICS
FIGURE 15 DRIVERS, RESTRAINT, OPPORTUNITIES AND CHALLENGE OF ASIA-PACIFIC SECONDARY HYPEROXALURIA DRUG MARKET
FIGURE 16 ASIA-PACIFIC SECONDARY HYPEROXALURIA DRUG MARKET: BY TYPE, 2020
FIGURE 17 ASIA-PACIFIC SECONDARY HYPEROXALURIA DRUG MARKET: BY TYPE, 2020-2028 (USD MILLION)
FIGURE 18 ASIA-PACIFIC SECONDARY HYPEROXALURIA DRUG MARKET: BY TYPE, CAGR (2021-2028)
FIGURE 19 ASIA-PACIFIC SECONDARY HYPEROXALURIA DRUG MARKET: BY TYPE, LIFELINE CURVE
FIGURE 20 ASIA-PACIFIC SECONDARY HYPEROXALURIA DRUG MARKET: BY DRUG TYPE, 2020
FIGURE 21 ASIA-PACIFIC SECONDARY HYPEROXALURIA DRUG MARKET: BY DRUGS CLASS, 2020-2028 (USD MILLION)
FIGURE 22 ASIA-PACIFIC SECONDARY HYPEROXALURIA DRUG MARKET: BY DRUG TYPE, CAGR (2021-2028)
FIGURE 23 ASIA-PACIFIC SECONDARY HYPEROXALURIA DRUG MARKET: BY DRUG TYPE, LIFELINE CURVE
FIGURE 24 ASIA-PACIFIC SECONDARY HYPEROXALURIA DRUG MARKET: BY POPULATION TYPE, 2020
FIGURE 25 ASIA-PACIFIC SECONDARY HYPEROXALURIA DRUG MARKET: BY POPULATION TYPE, 2020-2028 (USD MILLION)
FIGURE 26 ASIA-PACIFIC SECONDARY HYPEROXALURIA DRUG MARKET: BY POPULATION TYPE, CAGR (2021-2028)
FIGURE 27 ASIA-PACIFIC SECONDARY HYPEROXALURIA DRUG MARKET: BY POPULATION TYPE, LIFELINE CURVE
FIGURE 28 ASIA-PACIFIC SECONDARY HYPEROXALURIA DRUG MARKET: BY END USER, 2020
FIGURE 29 ASIA-PACIFIC SECONDARY HYPEROXALURIA DRUG MARKET: BY END USER, 2020-2028 (USD MILLION)
FIGURE 30 ASIA-PACIFIC SECONDARY HYPEROXALURIA DRUG MARKET: BY END USER, CAGR (2021-2028)
FIGURE 31 ASIA-PACIFIC SECONDARY HYPEROXALURIA DRUG MARKET: BY END USER, LIFELINE CURVE
FIGURE 32 ASIA-PACIFIC SECONDARY HYPEROXALURIA DRUG MARKET: BY DISTRIBUTION CHANNEL, 2020
FIGURE 33 ASIA-PACIFIC SECONDARY HYPEROXALURIA DRUG MARKET: BY DISTRIBUTION CHANNEL, 2020-2028 (USD MILLION)
FIGURE 34 ASIA-PACIFIC SECONDARY HYPEROXALURIA DRUG MARKET: BY DISTRIBUTION CHANNEL, CAGR (2021-2028)
FIGURE 35 ASIA-PACIFIC SECONDARY HYPEROXALURIA DRUG MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 36 ASIA-PACIFIC SECONDARY HYPEROXALURIA DRUG MARKET: SNAPSHOT (2020)
FIGURE 37 ASIA-PACIFIC SECONDARY HYPEROXALURIA DRUG MARKET: BY COUNTRY (2020)
FIGURE 38 ASIA-PACIFIC SECONDARY HYPEROXALURIA DRUG MARKET: BY COUNTRY (2021 & 2028)
FIGURE 39 ASIA-PACIFIC SECONDARY HYPEROXALURIA DRUG MARKET: BY COUNTRY (2021 & 2028)
FIGURE 40 ASIA-PACIFIC SECONDARY HYPEROXALURIA DRUG MARKET: BY TYPE (2021-2028)
FIGURE 41 ASIA-PACIFIC SECONDARY HYPEROXALURIA DRUG MARKET: COMPANY SHARE 2020 (%)
연구 방법론
데이터 수집 및 기준 연도 분석은 대규모 샘플 크기의 데이터 수집 모듈을 사용하여 수행됩니다. 이 단계에는 다양한 소스와 전략을 통해 시장 정보 또는 관련 데이터를 얻는 것이 포함됩니다. 여기에는 과거에 수집한 모든 데이터를 미리 검토하고 계획하는 것이 포함됩니다. 또한 다양한 정보 소스에서 발견되는 정보 불일치를 검토하는 것도 포함됩니다. 시장 데이터는 시장 통계 및 일관된 모델을 사용하여 분석하고 추정합니다. 또한 시장 점유율 분석 및 주요 추세 분석은 시장 보고서의 주요 성공 요인입니다. 자세한 내용은 분석가에게 전화를 요청하거나 문의 사항을 드롭하세요.
DBMR 연구팀에서 사용하는 주요 연구 방법론은 데이터 마이닝, 시장에 대한 데이터 변수의 영향 분석 및 주요(산업 전문가) 검증을 포함하는 데이터 삼각 측량입니다. 데이터 모델에는 공급업체 포지셔닝 그리드, 시장 타임라인 분석, 시장 개요 및 가이드, 회사 포지셔닝 그리드, 특허 분석, 가격 분석, 회사 시장 점유율 분석, 측정 기준, 글로벌 대 지역 및 공급업체 점유율 분석이 포함됩니다. 연구 방법론에 대해 자세히 알아보려면 문의를 통해 업계 전문가에게 문의하세요.
사용자 정의 가능
Data Bridge Market Research는 고급 형성 연구 분야의 선두 주자입니다. 저희는 기존 및 신규 고객에게 목표에 맞는 데이터와 분석을 제공하는 데 자부심을 느낍니다. 보고서는 추가 국가에 대한 시장 이해(국가 목록 요청), 임상 시험 결과 데이터, 문헌 검토, 재생 시장 및 제품 기반 분석을 포함하도록 사용자 정의할 수 있습니다. 기술 기반 분석에서 시장 포트폴리오 전략에 이르기까지 타겟 경쟁업체의 시장 분석을 분석할 수 있습니다. 귀하가 원하는 형식과 데이터 스타일로 필요한 만큼 많은 경쟁자를 추가할 수 있습니다. 저희 분석가 팀은 또한 원시 엑셀 파일 피벗 테이블(팩트북)로 데이터를 제공하거나 보고서에서 사용 가능한 데이터 세트에서 프레젠테이션을 만드는 데 도움을 줄 수 있습니다.
